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Surgical strategies to treat drug refractory left ventricular outflow tract obstruction (LVOTO) in 
hypertrophic cardiomyopathy (HCM) include septal myectomy (SM), and less frequently mitral valve 
(MV) repair or replacement. The primary aim of this study is to report surgical technique and 
management outcomes in a consecutive group of patients with variable phenotypes of HCM in a 
broad national specialist practice. 
Methods and Results 
203 consecutive patients, 132 males (mean age 48.6 +/- 14.6 years) underwent surgery for the 
management of LVOTO. Surgical approaches included SM (n=159), SM with MV repair (n=25), SM 
with MV replacement (n=9) and MV replacement alone (n=10). Specific surgical approaches were 
performed based on the underlying mechanism of obstruction. Eleven patients (5.4%) had previous 
alcohol septal ablation for management of LVOTO. Concomitant non-mitral cardiac procedures were 
carried out in 22 patients (10.8%). 
Operative survival rate was 99.0% with 2 deaths within 30 days. The mean bypass time was 92.9+/-
47.8 minutes with a mean length of hospital stay of 10.5+/-7.8 days. Surgical complications included 
3 ventricular septal defect’s requiring repair (1.5%), 1 Gerbode defect surgically repaired, 2 aortic 
valve repairs (1.0%), 2 transient ischaemic attack’s (1.0%) and 4 strokes (2.0%). Thirty-nine patients 
(19.2%) had perioperative new onset atrial fibrillation and 8 patients (3.9%) had unexpected 
atrioventricular block requiring a permanent pacemaker. Mean resting left ventricular outflow tract 
gradients improved from 70.6+/-40.3mmHg preoperatively to 11.0+/-10.5mmHg at 1 year (p<0.001). 
Mean NYHA Class improved from 2.6+/-0.5 preoperatively to 1.6+/-0.6 at 1 year. 
Conclusions 
In variable phenotypes of LVOTO in HCM, an individualised surgical approach achieved effective 
reductions in LVOT gradients and good symptomatic relief with acceptable mortality and morbidity. 
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Hypertrophic cardiomyopathy (HCM) is the commonest genetically inherited cardiac condition 
affecting 1 in 500 of the population. Complications include left ventricular outflow tract obstruction 
(LVOTO), atrial fibrillation (AF), ventricular arrhythmias, sudden cardiac death and heart failure.1-4 
Severe drug refractory symptoms can persist in up to one third of cases. Expert consensus indicates 
surgical intervention to be the gold standard in the management of these patients.2 Septal myectomy 
(SM) alone, is the surgical technique of choice in the vast majority of patients with HCM with 
excellent outcomes.6-12 The mechanism of LVOTO can be complex with a varying non-classical 
phenotype also seen in HCM. This includes limited septal hypertrophy, angulation of the aorta, 
elongation of mitral leaflets and abnormalities of the sub-mitral apparatus. Abnormal mitral 
attachments include thickened or anteriorly displaced papillary muscles, direct insertion of the 
papillary muscle into the anterior mitral valve leaflet or fibrotic chordal attachments.5 These non-
classical phenotypes may, in individual circumstances, dictate a different surgical approach. With an 
improved understanding of the mechanism of obstruction, an increasing number of mitral valve (MV) 
repairs and replacements are performed both concomitantly with SM, or alone. The primary aim of 
this study is to evaluate early outcomes following individualised surgical strategies for the 





Between 2003 and 2015, 203 consecutive patients underwent surgical intervention for the 
management of LVOTO in HCM in a national specialised cardiomyopathy unit at the Heart Hospital, 
University College London Hospital. No patients were excluded. All patients were operated on by one 
of two surgeons (CMcG, VT). 
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Clinical assessment 
All patients were assessed in a clinic specialising in cardiomyopathy. Baseline demographic data 
including age, sex, past medical and family history were documented, as was pre and postoperative 
New York Heart Association (NYHA) functional class. Variables from transthoracic 
echocardiography (TTE) including interventricular septal wall thickness (IVS), posterior wall 
thickness (PWT), left ventricular end diastolic diameter (LVEDD), left atrial diameter (LAD), left 
ventricular ejection fraction (EF), resting and provoked left ventricular outflow tract gradients 
(LVOT) and severity of mitral and aortic regurgitation were collected. Drug refractory symptomatic 
LVOTO with a LVOT gradient >50mmHg was the principal indication for surgery as per 
international guidelines.2 All patients were discussed at a joint medical and surgical cardiac 
conference and the most suitable surgical approach discussed. Particular attention was paid to the MV 




After median sternotomy and before cardiopulmonary bypass, direct simultaneous pressure 
measurements were performed with needles in the aorta and left ventricle. Provocation was measured 
following a bolus of Isoproterenol (5mcg) intravenously and repeated if an increase in heart rate 
and/or reduction in blood pressure was not achieved. Over the time of the study the surgical technique 
of SM evolved from the classical Morrow myectomy to the Danielson modification of the classic 
Morrow myectomy.13,14 After the initial planned surgery and cessation of cardiopulmonary bypass, 
transoesophageal echocardiography (TOE) was done to assess the LVOT and MV. Direct 
simultaneous pressure measurements were repeated with and without provocation as done pre-bypass. 
Indications to resume bypass and perform further surgery at this point were principally a significant 
residual gradient, and/or persistent SAM related MR. Mitral valve repairs included trans-atrial Alfieri 
edge to edge repair, transaortic mitral plication, cleft repair, division of papillary muscles or artificial 
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chordal repair. Mitral annuloplasty was avoided in all patients. Mitral valve replacement was done at 
the time of SM using standard techniques and MV replacement was done alone without SM again 
using standard techniques. Perioperative complications were defined as those occurring within the 
first 30 days following surgery. 
 
Follow up 
All patients were followed up clinically at regular annual visits or more frequent intervals based on 
clinical status. At 1 year, postoperative echocardiographic data was available in 83.7% of patients. 
The remainder of patients were followed up by their local cardiologist. 
 
Statistical analysis 
Variables were collected and assessed using SPSS software, version 24 (IBM, Chicago). Tests of 
normality were carried out based on histogram distribution and the Shapiro-Wilks test. For data with a 
normal distribution, continuous variables were expressed as a mean ± standard deviation. For data 
with a non-normal distribution, continuous variables were expressed as a median with interquartile 
range. For normally distributed data, comparison of means was performed using a paired student t 
test. For non-normally distributed data comparisons were performed using a Mann Whitney U test. 
All echocardiographic variables were normally distributed and comparison of means was performed 




Of the 203 patients in the study, baseline demographics are documented in Table 1. The mean age at 
surgery overall was 48.6+/-14.6 and in those undergoing a SM alone was 47.5 +/- 14.2 years, SM 
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with MV Repair was 48.7+/- 15.0 years, SM with MV replacement was 55.4 +/- 15.0 years and MV 
replacement alone was 57.7 +/- 14.3 years. Eleven patients (5.4%) previously underwent alcohol 
septal ablation for the management of LVOTO with recurrence of symptoms. 
 
Surgery 
The mean cardiopulmonary bypass-time was 92.9+/-47.8 minutes with a mean length of hospital stay 
of 10.5+/-7.8 days. The mean weight of septal tissue removed, available in 87 patients (42.3%), 
weighed 6.6+/-4.3 grams. Surgical procedures are illustrated in Table 2. One hundred and fifty-nine 
patients (78.3%) had a SM alone. Twenty-five patients (12.3%) had a SM with MV repair which 
included edge-to-edge (Alfieri) repair, valve plication, cleft repair, chordal repair and division of 
papillary muscle. Nine patients (4.4%) underwent a SM with MV replacement, two of which were 
bioprosthetic MV replacements. In 6 of these 9 patients concomitant MV replacements were 
unplanned following unsuccessful repair, the remainder were planned replacements. Four of these 6 
patients had degenerative MV disease with residual moderate to severe MR following initial bypass 
and SM. The other 2 patients had a MV repair after SM with residual moderate to severe MR. None 
of these 6 patients had residual SAM following the initial SM. Ten patients (4.9%) had a MV 
replacement alone without a SM, one of which was a bioprosthetic MV replacement. Other 
concomitant procedures included coronary artery bypass grafting (n=4), aortic valve replacement 
(n=3), surgical MAZE with or without pulmonary vein radiofrequency ablation (n=9), resection of 
subaortic membrane (n=7), closure of a patent foramen ovale (n=3) or atrial septal defect (n=1). 
Forty-six patients (22.7%) underwent closure of the left atrial appendage at the time of surgery. 
Thirteen patients (6.4%) of the 203 patients required reinstitution of cardiopulmonary bypass 
following initial SM. This was required for a mitral valve repair due to residual SAM/MR (n=7), a 
MV replacement for residual MR following initial repair (n=2) and a MV replacement directly 
without an intermediate repair attempt (n=4). Anatomical and echocardiographic indications for 




Operative survival was 99.0% with 2 perioperative deaths within 30 days of surgery. One patient, a 
67-year-old female sustained a ventricular septal defect (VSD) identified on an intraoperative 
transoesophageal echocardiogram (TOE) following a SM with staple excision of the left atrial 
appendage. This was repaired immediately through a right ventriculotomy using bovine pericardial 
patches and continuous prolene sutures to close the defect and the right ventricle. This patient 
developed progressive low cardiac output and died on day 3. A second patient, a 30-year-old male, 
undergoing an extended SM for severe concentric left ventricular hypertrophy and pulmonary vein 
isolation for the management of AF developed an aortic valve tear to the left coronary cusp which 
was repaired using two 8-0 prolene sutures. This patient died on day 3 from heart failure in the setting 
of aortic regurgitation, severe diastolic dysfunction and external pacemaker dysfunction. Survival at 1 
year was 98.5% with 1 further death at 4 months due to heart failure postoperatively. There were no 
other deaths within the first year of surgery. 
 
Complications 
Fifty-six patients (27.6%) had documented postoperative AF, thirty-nine of which were new onset of 
postoperative AF. There were 2 perioperative TIA’s (1.0%) with 4 perioperative strokes (2.0%). One 
stroke was assumed cardioembolic in nature in the setting of new onset AF. The remaining cases had 
no documented AF. Thirteen patients (6.4%) had a permanent pacemaker (PPM) device inserted for 
atrioventricular block. Five of these 13 patients had a planned prophylactic insertion of a permanent 
pacemaker for pre-existing high grade atrioventricular block during the primary surgical admission. 
These patients were deemed at high risk for complete heart block with the additional inevitable left 
bundle branch block from SM. Eight further patients (3.9%) developed unexpected atrioventricular 
block requiring permanent pacemaker insertion. Ten patients (4.9%) had an implantable cardioverter 
device (ICD) in the perioperative period, 3 of which were implanted to treat complete atrioventricular 
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block in the setting of associated risk factors for sudden cardiac death. The remaining 7 patients had 
an ICD implanted based on risk factors associated with SCD. As described above, 3 patients (1.5%) 
suffered a VSD requiring repair intraoperatively. One additional patient developed an acquired 
Gerbode defect postoperatively which was successfully surgically repaired.15 Two patients (1.0%) had 
an unplanned aortic valve repair due to a new valve tear intraoperatively. Two patients (1.0%) 
required further operative intervention during the initial surgical stay. These patients who initially 
underwent SM with MV repair required reintervention with MV replacement on day 4 and 14 
respectively due to severe MR.  
 
Clinical and Echocardiogrpahic Outcomes 
The mean NYHA Class improved from 2.6+/-0.5 preoperatively to 1.6+/-0.6 postoperatively at 1 year 
(p<0.001). The vast majority of patients improved symptomatically with 78.7% of patients improving 
by at least one NYHA class postoperatively, with 19.5% of patients remaining in the same NYHA 
functional class and a minority of patients (1.7%) in a higher NYHA function class at 1 year. 
Echocardiographic variables are shown in Table 4. The mean IVS wall thickness reduced from 
19.1+/-4.1mm preoperatively to 13.9+/-4.0mm postoperatively (p<0.001). Resting LVOT gradients 
reduced from 70.6+/-40.3 preoperatively to 11+/-10.5mmHg after surgery at 1 year (p<0.001). One 
hundred and eighty-three patients (90.1%) had no evidence of resting or provoked LVOTO on the 
postoperative echocardiogram at 1 year. Individual NYHA class and MR grade are compared pre and 
postoperatively in Table 5. 
 
Discussion 
Surgical management of LVOTO by SM is considered by expert consensus to be the gold standard in 
the management of drug refractory symptomatic cases in HCM, with excellent outcomes in the vast 
majority of cases.2 Multiple large surgical series have reported the outcomes of SM alone, which 
reflect in part, referral patterns to large US centers.7,9,10 The earliest surgical approaches included the 
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standard SM introduced by Morrow et al. (1961) and MV replacement by Cooley et al. (1971); both 
of which have been shown to be successful in improving symptoms and alleviating LVOT 
gradients.14,16 In the vast majority of patients, SM is the only procedure required to treat LVOTO in 
HCM. Mitral abnormalities however, do play an important role in the mechanism of LVOTO in 
individual patients such as those with limited hypertrophy, and we believe an individualised surgical 
approach is necessary for optimal surgical management.5 The current series reflects experience of 
surgery for LVOTO in HCM in a national centre with referral of a wide phenotypic variation 
performing >70% of such UK practice over the period of the study. 
 
Preoperative and intraoperative imaging, including TTE and TOE are essential in the characterisation 
of phenotypic abnormalities to allow for strategic surgical planning to address causes of MR and 
SAM. Intrinsic MV abnormalities can pre-exist including annular, leaflet or chordal calcification or 
fibrosis which may need to be addressed at the time of operation. Specific abnormalities of the MV 
apparatus, commonly seen in HCM patients can contribute to the mechanism of LVOTO including 
both elongation of MV leaflets and abnormal mitral attachments.17 Abnormal MV attachments, 
commonly seen with LVOTO include anterior papillary muscle displacement, thickened bifid 
papillary muscles, direct insertion of papillary muscle into the AMVL or fibrotic chordal attachments. 
Complex cases with involvement of both the mitral and submitral apparatus can be managed with a 
combination of SM and repair or replacement of the MV. The use of an extended SM can address this 
issue somewhat by extending the resection in a fan like fashion moving distally in the septum. Ferrazi 
et al. report good outcomes in patients undergoing a limited SM with trans aortic selective division of 
fibrosed secondary chordae attached to the AMVL body believed to be contributing to SAM.18 
Elongation of the MV leaflets, in particular the anterior leaflet result in SAM related MR. In cases of 
limited septal hypertrophy, MV replacement has been performed as primary surgery in the past, 
however, a range of newer surgical techniques for MV repair have evolved to address such cases in 
which adequate resection is technically challenging.19-21 Controversy remains over individual 
techniques of MV repair in patients with LVOTO. The rate of concomitant MV intervention with SM 
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has varied from 8% in a recent large study of over 2000 patients from the Mayo Clinic operated on 
with SM for LVOTO to 25% in a paper from the Cleveland Clinic.7,11  
 
Multiple surgical approaches have been advocated in the presence of elongated leaflets with post SM 
SAM and/or MR with good outcomes, including the edge to edge Alfieri repair, MV plication and 
AMVL extension using a pericardial patch.19-21 The edge to edge Alfieri mitral valve repair was our 
preferred surgical approach to address elongated anterior mitral leaflets with SAM related MR with 
good resolution of LVOT gradients and improved symptoms. This was done using a trans-atrial rather 
than trans-aortic approach which allowed us to inspect the submitral apparatus in more detail. The 
Alfieri technique has been used successfully in MR of various aetiologies.21 There have been no early 
or late mortalities in this group of 11 patients in the current study, who documented good medium 
term outcomes.22 If an Alfieri repair is contemplated, assessment of the posterior MV leaflet length is 
important, as excess length can lead to bileaflet prolapse with SAM making this type of repair less 
likely to be effective. 
 
The advantage of MV repair is that it obviates the need for MV replacement and its associated 
complications.23 Late survival following SM with MV repair was superior to SM with MV 
replacement in the large Mayo clinical experience.11 Contemporary data on MV replacement alone for 
relief of LVOTO in HCM in the literature is less robust than that for SM. Initial studies reported by 
Cooley et al. showed good symptomatic relief and resolution of gradients. Further long-term studies 
by the same group showed good outcomes at ten years.24 Other early studies showed similar 
symptomatic and gradient reduction with MV replacement, however, higher mortality rates and 
complication rates were seen in these cohorts.25,26 More recent studies of MV replacement in patients 
with LVOTO have reported on SM with MV replacement rather than MV replacement alone.11,27,28,29 
Mitral valve replacement alone can be a successful approach in cases unsuitable for repair or when 
used alone in those patients with thinner septae unsuitable for SM.  
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In the early part of the series, there were few concomitant MV procedures performed. With an 
improved understanding of the mechanism of obstruction, over time, more complex HCM phenotypes 
were operated on particularly in older patients with concomitant cardiac disease with an increasing 
number of MV repairs and replacements. The decision to proceed with a MV replacement directly, 
rather than a further bypass run to explore a potentially intermediate MV repair was carefully 
considered. In this study it was noted that patients who required MV replacement were older and had 
more comorbidities than those who did not require a MV replacement. The preoperative phenotype as 
well as cardiac and non-cardiac comorbidities were factored into the surgical decision making process 
i.e. in consideration of the tolerance of a more extensive, longer operation. In selected older patients 
with atypical phenotypes and multiple comorbidities in whom SM alone was felt unlikely to be 
adequate and who were felt to be unsuitable for multiple bypass runs, an upfront decision to perform 
MV replacement alone was made in this series. 
 
Figure 1, illustrates a flowchart for consideration in the strategic planning of surgery in the 
management of non-classical LVOTO in HCM. These phenotypes include aortic angulation, limited 
hypertrophy or abnormally distributed hypertrophy along with abnormalities of the MV commonly 
including elongated leaflets, abnormal MV attachments or other intrinsic abnormalities of the MV. A 
stepwise approach is taken in the planning of individual cases which is re-evaluated intraoperatively 
following the initial procedure and initial bypass run to evaluate if further intervention is needed to 
the MV. The recent Mayo study of 174 patients surgically managed with SM and MV intervention 
revealed no difference in ICU length of stay, hospital length of stay or late mortality in those 
undergoing single or multiple cardiopulmonary bypass runs indicating the safety of this approach in 
appropriate patients.11  
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Hospital volume plays an important role in mortality outcomes of surgery for HCM. A recent national 
database study analysing 6386 SM’s reported that surgery in lower volume centres was an 
independent predictor of mortality in the USA.30 In high volume centres early surgical outcomes 
following SM have shown very low mortality rates with good resolution of symptoms.6,7,10,30 
Mortality within this current study is low and comparable to current reported outcomes in high 
volume centres for SM.9 Additionally, 21.7% of patients included in the current study had MV 
surgery and 10.8% had concomitant non-mitral surgery. This study reports good echocardiographic 
follow up with 83.7% of all patients at 1 year, a rate which is not available in many other studies of 
this size. Almost 80% of patients in this study showed an improvement in NYHA class 
postoperatively comparable to previous large studies.10,12 Over 90% of patients demonstrated a 
resolution of obstruction with a LVOT gradient of <30mmHg on postoperative echocardiography at 1 
year. This individualised approach to the management of LVOTO in variable phenotypes of HCM 
adopted by our institution has not compromised, at least, 1 year surgical, clinical and 
echocardiographic outcomes. 
Limitations 
This study represents a single centre, retrospective consecutive experience representing limitations 
inherent to this study design. We acknowledge that as a national referral centre with a large 
population of HCM patients attending for regular clinical review that this may introduce referral bias, 
however, we believe that, a more variable set of phenotypes may be seen within such an environment, 
requiring a more individualised surgical approach. There was incomplete data on the exact 
distribution of hypertrophy from echocardiography in individual patients. 
 
Conclusion 
This study from a single centre experience reports individualised surgical approaches to the 
management of LVOTO in HCM with low mortality rates and good clinical outcomes. Surgical 
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strategy should be individualised depending on the underlying mechanism of obstruction with 
appropriate evaluation of the MV. 
 












































Overall number of patients 203 (100%) 
(  ) = % of total 
Age at Surgery (mean+/-SD) 48.6+/-14.6 
Male 132 (65.0%) 
Past History 
 
Atrial Fibrillation 28 (13.8%) 
Previous PPM 14 (6.9%) 
Previous PPM for LVOTO 9 (4.4%) 
Previous ASA 11 (5.4%) 
Stroke 3 (1.5%) 
Peripheral Vascular Disease 1 (0.5%) 
Diabetes Mellitus 9 (4.4%) 
Hypertension 58 (28.6%) 







Overall number of patients 203 (100%) 
(  ) = % of total 
Septal Myectomy 159 (78.3%) 
Septal Myectomy with MV repair 
Plication 
Edge-to-edge Alfieri repair 
Cleft repair 








Septal Myectomy with MV replacement 9 (4.4%) 
MV replacement alone 10 (4.9%) 
Concomitant Procedures (in 22 patients) 
CABG 
Planned aortic valve replacement 
MAZE 
Resection of subaortic membrane 
Closure of PFO 












Category of MV 
intervention (N = 

























1 0 0 0 0 0 1 1 
Cleft Repair (N=3) 0 0 1 0 0 0 3 3 
Plication (N=4) 1 1 3 0 0 1 4 4 
Chord Repair (N=6) 1 0 0 3 2 1 4 5 
Alfieri (N=11) 4 3 5 2 1 2 9 10 
SM and MV 
replacement (N=9) 
2 1 3 2 3 1 9 9 
MV replacement 
alone (N=10) 
7 1 1 0 6 0 7 9 
Table 3: Anatomical and echocardiographic features in individual surgical mitral interventions. 
Numbers in each vertical column represent the number of patients with the listed specific feature. 
ASH: Asymmetric Septal Hypertrophy 
AMVL: Anterior MV Leaflet 















IVS (mm) 19.1+/-4.1 13.9+/-4.0 <0.001 
PWT (mm) 10.8+/-2.8 10.1+/-2.3 0.022 
LAD (mm) 47.2+/-7.7 45.8+/-7.1 0.002 
LAA (cm2) 30.6+/-8.0 27.1+/-7.0 0.003 
LVEDd (mm) 46.0+/-5.9 48.9+/-6.3 <0.001 
EF (%) 69.0+/-6.8 62.1+/-8.4 <0.001 
Resting Grad (mmHg) 70.6+/-40.3 11.0+/-10.5 <0.001 
Provoked Grad (mmHg) 91.1+/-39.8 24.5+/-32.0 <0.001 
MR grade 2.4+/-0.9 1.4+/-0.7 
 











 Overall (n=203) SM Alone (n=159) MV Intervention (n=44) 
 Preop Postop Preop Postop Preop Postop 
NYHA Class 
1 2.0% 47.4% 2.6% 45.7% 0% 53.8% 
2 36.7% 48.6% 37.3% 50.0% 34.1% 43.6% 
3/4 61.3% 4.0% 60.1% 4.3% 65.9% 2.6% 
MR Grade 
0/1 14.2% 52.9% 17.3% 51.2% 2.4% 59.5% 
2  42.4% 43.0% 44.7% 44.4% 34.1% 37.8% 
3  31.9% 4.1% 29.3% 4.4% 41.5% 2.7% 
4 11.5% 0% 8.7% 0% 22.0% 0% 
Table 5: Comparison of individual NYHA Class and MR grade pre and postoperatively overall and in 
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